In contrast Cellmid:
- has extensive diagnostics experience;
- board members and scientific advisors who are capable and trusted by Government to complete an internal results based study of the Wondfo POCTS.
- is commencing with a relative small order of tests, thus keeping the company's risk exposure down.
I want to see the Cellmid under promise and over deliver (not the other way around).
On the POCTS themselves, they need to be used only for their intended purpose and very carefully by trained health care workers. Rough-house use in the field will lead to inaccurate results with most test including this one.
- Forums
- ASX - By Stock
- AN1
- Ann: Cellmid Signs COVID-19 Rapid Diagnostic Supply Agreement
Ann: Cellmid Signs COVID-19 Rapid Diagnostic Supply Agreement, page-1065
-
- There are more pages in this discussion • 206 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online